Semaglutide
- Category
- Weight Management & Metabolic
- Administration routes
- Injectable
- Regulatory status
- FDA-approved
What it is
A modified GLP-1 receptor agonist marketed for weight loss and type 2 diabetes. Human evidence is strong, with large trials backing weight loss, glycemic control, and cardiovascular benefits, though neuroprotective claims stay speculative. Main risk is GI side effects in many users, plus a boxed thyroid-tumor warning (animal studies) and contraindication in MEN 2 or medullary thyroid cancer history. FDA-approved; obtain only through a licensed prescriber.
Read Full recordStudied uses & evidence
Studied uses(7)
Significant weight loss
HighLarge randomized trial showed 14.9% body weight loss versus 2.4% with placebo.
Type 2 diabetes control
HighMultiple large trials showed HbA1c reductions of 1 to 1.8 percentage points versus placebo.
Cardiovascular risk reduction
HighTwo large outcome trials showed roughly 20 to 26% fewer major cardiovascular events.
Evidence limits
- Evidence Level
- Level 1 — Strong
Over 40,000 participants across dozens of Phase 3 RCTs. Evidence supports weight loss, T2DM, CV risk reduction, CKD.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
Do not use if
Personal/family history of medullary thyroid carcinoma (MTC)
AbsoluteGLP-1 agonists caused thyroid C-cell tumors in rodents. Contraindicated in MTC or MEN2 syndrome.
Type 1 diabetes
AbsoluteNot indicated for T1DM. Risk of diabetic ketoacidosis.
History of pancreatitis
HighGLP-1 agonists may increase pancreatitis risk. Use with extreme caution if prior pancreatitis.
Severe gastroparesis
HighSemaglutide slows gastric emptying. Can worsen severe gastroparesis significantly.
Severe renal impairment
ModerateGI side effects (nausea, vomiting) may worsen dehydration and renal function.
General cautions
Pregnancy or planning pregnancy
AbsoluteDiscontinue at least 2 months before planned conception. Animal studies show fetal harm.
Risk summary(7)
Risks = level of concern: High · Moderate · Low · Theoretical
GI side effects: nausea (20-44%), vomiting, diarrhea, constipation
HighBoxed warning: thyroid C-cell tumors in animal studies (human relevance unclear)
ModeratePancreatitis risk (rare)
LowGallbladder disease risk
ModerateAcute kidney injury (rare, usually from dehydration due to GI effects)
LowDiabetic retinopathy complications
ModerateContraindicated: personal/family history of medullary thyroid carcinoma or MEN 2
High
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Prescribing labels in Full record
- Monitoring & labs in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.